STOCK TITAN

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (APLS) will participate in upcoming investor conferences in March 2024, including TD Cowen 44th Annual Healthcare Conference and Raymond James & Associates’ 45th Annual Institutional Investors Conference. The company will host fireside chats and panel discussions, with live webcasts available on their website.
Positive
  • None.
Negative
  • None.

WALTHAM, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following March investor conferences:

  • TD Cowen 44th Annual Healthcare Conference:
    • Fireside chat on Monday, March 4, 2024, at 2:10 p.m. ET
    • Ophthalmology Corporate Panel Discussion on Tuesday, March 5, 2024, at 9:10 a.m. ET
  • Raymond James & Associates’ 45th Annual Institutional Investors Conference: Fireside chat on Tuesday, March 5, 2024, at 11:00 a.m. ET

The live conference webcasts will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcasts will be available for approximately 90 days following the event.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.

Investor Contact: 
Meredith Kaya 
meredith.kaya@apellis.com
617.599.8178


Apellis Pharmaceuticals will have a fireside chat on Monday, March 4, 2024, at 2:10 p.m. ET at the TD Cowen 44th Annual Healthcare Conference.

On Tuesday, March 5, 2024, Apellis Pharmaceuticals will participate in the Ophthalmology Corporate Panel Discussion at 9:10 a.m. ET and host a fireside chat at the Raymond James & Associates’ 45th Annual Institutional Investors Conference at 11:00 a.m. ET.

The live conference webcasts will be available on the “Events and Presentations” page of the “Investors and Media” section on Apellis Pharmaceuticals' website.

The replay of the webcasts will be accessible for approximately 90 days following the investor conferences.
Apellis Pharmaceuticals Inc

NASDAQ:APLS

APLS Rankings

APLS Latest News

APLS Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Distribution Services, Medical Distributors, Health Technology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
United States
Waltham

About APLS

apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.